Celltrans Report issue

Contributed to NME Academic/Hospital

Organization Overview

First Clinical Trial
None
First Marketed Drug
2023
donislecel-jujn (Lantidra)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

CellTrans Inc.

Active Ingredients

Marketed Drugs (1)

donislecel-jujn (Lantidra) (2023 NDA)

Drugs in Other Trials (1)

allogeneic pancreatic islet cells (1 trial)

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 1
  • # of Trial APIs: 1